OBJECTIVE: To compare and analyze the adverse drug reactions（ADR） of domestic and imported iodixanol injection during clinical application

so as to provide data support for clinical rational application. METHODS: All the patients treated with iodixanol injection in the hospital from 2020 to 2021 were analyzed

which were divided into three groups according to the manufacturer of iodixanol injection（two groups of domestic iodixanol injection and one group of imported iodixanol injection）

the general information of patients with ADR

as well as the severity

occurrence time and clinical manifestations of ADR were collected. RESULTS: Totally 29 335 patients treated with iodixanol injection were enrolled

and 116 cases of ADR occurred

with the incidence rate of 0.40%. There was no statistical significance in difference in the incidence of ADR among the three groups（P>0.05）; there were no statistical significance in differences in the male-female ratio

average age and proportion of basic diseases among the three groups（P>0.05）; there was no statistical significance in differences in the severity

occurrence time and clinical manifestations of ADR（P>0.05）. CONCLUSIONS: The two kinds of domestic iodixanol injection and imported iodixanol injection had the lower incidence of ADR

and the ADR were non-severe

which is comparable in terms of clinical use safety.